
LCMV (strain Armstrong) Nucleoprotein 118-126, RPQASGVYM
Description
About LCMV (strain Armstrong) Nucleoprotein 118-126, RPQASGVYM
The Lymphocytic choriomeningitis virus (strain Armstrong) Nucleoprotein Peptide (IEDB: 55289) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Nucleoprotein Peptide, H-RPQASGVYM-OH (Uniprot: P09992 aa: 118-126) from JPT is produced under strict quality control and quality management.
LCMV (strain Armstrong) Nucleoprotein 118-126, RPQASGVYM - Specifications
- Peptide sequence: H-RPQASGVYM-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Lymphocytic choriomeningitis
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for LCMV (strain Armstrong) Nucleoprotein 118-126, RPQASGVYM
References:
Read References with JPT’s Antigen Peptides
LCMV (strain Armstrong) Nucleoprotein 118-126, RPQASGVYM has been described in:
Single-epitope DNA vaccination prevents exhaustion and facilitates a broad antiviral CD8+ T cell response during chronic viral infection., J Immunol, 2004 (PMID: 15528367)
Common antiviral cytotoxic t-lymphocyte epitope for diverse arenaviruses., J Virol, 2001 (PMID: 11413293)
Approach for Identifying Human Leukocyte Antigen (HLA)-DR Bound Peptides from Scarce Clinical Samples., Mol Cell Proteomics, 2016 (PMID: 27452731)
Documentation
Documentation for LCMV (strain Armstrong) Nucleoprotein 118-126, RPQASGVYM
Properties
Properties of LCMV (strain Armstrong) Nucleoprotein 118-126, RPQASGVYM
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Lymphocytic choriomeningitis |
Layout: | Freeze-dried in glass vial |
Organism: | Lymphocytic choriomeningitis virus |
Protein Name: | Nucleoprotein |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to LCMV (strain Armstrong) Nucleoprotein 118-126, RPQASGVYM
Information | Values |
---|---|
Sequence: | H-RPQASGVYM-OH |
Specifications: | 9mer peptide as TFA salt |